Non-Hodgkin Lymphoma

The European Commission has approved the rituximab (Rituxan) biosimilar Rixathon (GP2013) to treat patients with follicular lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia.

Jeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the TRANSCEND study, which is exploring the CD19-directed chimeric antigen receptor (CAR) T-cell therapy JCAR017 in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Treatment with JCAR017 demonstrated a complete response rate of 59% and an objective response rate of 86% for patients with relapsed or refractory diffuse large B-cell lymphoma.

Combining pembrolizumab with rituximab induced a high response rate in patients with relapsed follicular lymphoma.

Copanlisib showed an objective response rate of 59.2% without inducing major colitis events or elevation of hepatic transaminases in patients with relapsed or refractory indolent B-cell lymphoma.

At more than 40 months’ follow-up, combining obinutuzumab with chemotherapy in the first-line setting reduced the risk of disease progression or death by 32% versus rituximab plus chemotherapy in patients with follicular lymphoma.

Combining the novel BTK inhibitor BGB-3111 with the CD-20 antibody obinutuzumab demonstrated clinical activity and was well tolerated in patients with chronic lymphocytic leukemia/small lymphocytic leukemia or follicular lymphoma.

Neil L. Berinstein, MD, professor, University of Toronto, Sunnybrook Health Sciences Centre, discusses combination treatments for patients with high-risk or recurrent follicular lymphoma.

Copanlisib (BAY 80-6946), a novel PI3K inhibitor, is being combined with standard rituximab-based regimens in patients with relapsed, indolent non-Hodgkin lymphoma.

Connie Batlevi, MD, PhD, discusses the combination of ibrutinib and buparlisib in MCL.

Tazemetostat (EPZ-6438) demonstrated strong clinical activity in patients with advanced EZH2-mutated follicular lymphoma, and was also active in patients with diffuse large B-cell lymphoma.

Ian W. Flinn, MD, PhD, discusses the 5-year update of the BRIGHT study in MCL and NHL.

Loretta J. Nastoupil, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses high response rates with prembrolizumab (Keytruda) in combination with rituximab (Rituxan) in patients with relapsed follicular lymphoma.

Sattva Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-1 trial investigating axicabtagene ciloleucel (axi-cel; KTE-C19) for patients with refractory aggressive non-Hodgkin lymphoma.

Sarah Rutherford, MD, discusses rare DLBCL subtypes, ongoing research to improve outcomes for these patient populations, and the potential role of CAR T-cell therapy.

Patients with refractory aggressive non-Hodgkin lymphoma lacking curative treatment options demonstrated high response rates and durable responses plus a manageable safety profile following treatment with axicabtagene ciloleucel.

Tisagenlecleucel-T (CTL019) met its primary endpoint for best objective response rate in patients with relapsed or refractory diffuse large B-cell lymphoma.

Brad S. Kahl, MD, professor, Department of Medicine, Oncology Division, Washington University School of Medicine, discusses ADCT-402 for patients with relapsed/refractory B-cell lineage non-Hodgkin lymphoma.

The FDA has granted a priority review to axicabtagene ciloleucel for transplant-ineligible patients with relapsed or refractory non-Hodgkin lymphoma.

Researchers using cell-of-origin classification connected dual expression of the proteins MYC and BCL2 with poorer survival in patients undergoing chemotherapy for diffuse large B-cell lymphoma.

Daniel J. Landsburg, MD, discusses the management of patients with double-hit lymphoma who have achieved remission.

The FDA has granted a priority review designation to copanlisib as a treatment for patients with relapsed/refractory follicular lymphoma who have received at 2 least prior therapies, according to Bayer, the manufacturer of the PI3K dual-isoform inhibitor.

Results from the phase III SABRINA trial showed that subcutaneous administration of rituximab produced nearly identical response rates and toxicity as IV administration in the first-line treatment of follicular lymphoma.

The first cerebral edema death in the ZUMA-1 CAR T-cell therapy trial was disclosed today by Kite Pharma on a conference call with investors announcing the company’s first quarter financial results.

Sattva S. Neelapu, MD, discusses the ZUMA-1 trial and the potential impact of these results on patients with non-Hodgkin lymphoma.